Especially, recent studies have shown that (TA)MUC1 due to its strong expression in HR-positive 35,36, HER2/neu-positive breast tumors 14 and in TNBCs 11, is crucially involved in the development of resistance to the clinically used adjuvant therapies (tamoxifen, trastuzumab, systemic chemotherapy). This evidence concerns the gene ERBB2 and breast neoplasm.